Drugs / ERX-315
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06533332 | Oct 2024 → Dec 2026 expected | breast cancer, endometrial cancer, liver cancer, malignant pancreatic neoplasm +1 | EtiraRx Australia Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | EtiraRx Australia Pty Ltd | Results One Year on ERX-315 etira.life ↗
Etira today announced that a patient enrolled in its ongoing Phase 1 clinical trial of ERX-315 (NCT06533332) has now remained on treatment for more than one year. |
| 2025-06-26 | EtiraRx Australia Pty Ltd | Results Progress in ERX-315 Phase 1 Clinical Trial etira.life ↗
Etira , a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical trial of investigational drug ERX-315 ( NCT06533332 ). |
| 2025-04-24 | EtiraRx Australia Pty Ltd | Results Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025 etira.life ↗
These abstracts will establish ERX-208 as a powerful breakthrough in ovarian cancer treatment, rigorously assess synergy of ERX-208 with FDA-approved drugs, and validate ERX-315, an Etira drug in Phase 1 trial (NCT06533332), for impact in liver cancer. |
| 2024-08-01 | EtiraRx Australia Pty Ltd | Regulatory ERX-315 CLINICAL TRIAL APPROVED BY HREC etira.life ↗
Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). |
| 2024-05-15 | EtiraRx Australia Pty Ltd | Regulatory ERX-315 SUBMITTED FOR HREC APPROVAL etira.life ↗
Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. |
| 2023-12-07 | EtiraRx Australia Pty Ltd | Results ERX-315 introduced at SABCS 2023 etira.life ↗
Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms of endocrine therapy resistant breast cancer, including those driven by mutant estrogen receptor. |
All press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | EtiraRx Australia Pty Ltd | One Year on ERX-315 etira.life ↗ |
| 2025-06-26 | EtiraRx Australia Pty Ltd | Progress in ERX-315 Phase 1 Clinical Trial etira.life ↗ |
| 2025-04-24 | EtiraRx Australia Pty Ltd | Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025 etira.life ↗ |
| 2025-03-17 | EtiraRx Australia Pty Ltd | Second site activated for ERX-315 trial etira.life ↗ |
| 2025-02-20 | EtiraRx Australia Pty Ltd | ERX-315 Phase 1 Clinical Trial Update etira.life ↗ |
| 2024-11-18 | EtiraRx Australia Pty Ltd | First patient dosed in ERX-315-101 Clinical Trial etira.life ↗ |
| 2024-09-04 | EtiraRx Australia Pty Ltd | ERX-315-001 SITE INITIATION VISIT @TKCC etira.life ↗ |
| 2024-08-01 | EtiraRx Australia Pty Ltd | ERX-315 CLINICAL TRIAL APPROVED BY HREC etira.life ↗ |
| 2024-05-15 | EtiraRx Australia Pty Ltd | ERX-315 SUBMITTED FOR HREC APPROVAL etira.life ↗ |
| 2023-12-07 | EtiraRx Australia Pty Ltd | ERX-315 introduced at SABCS 2023 etira.life ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERX-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533332 ↗ |
| Route | Intravenous | “intravenous (IV) injection” NCT06533332 ↗ |